Paper28107479
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.
Mpakou V and 13 others. PLoS One, 2017. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. Papers, record 28107479. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28107479
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Apoptosis | Major topic |
| Bortezomib | Major topic |
| Gene Expression Profiling | Major topic |
| Lymphoma, T-Cell, Cutaneous | Major topic |
| Methotrexate | Major topic |
| Cell Line, Tumor | |
| DNA Repair | |
| Flow Cytometry | |
| Humans | |
| Polymerase Chain Reaction | |
| Signal Transduction |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14202592 | OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES. | Cancer | 1964 | https://conductscience.org/library/papers/14202592 | PubMed |
| 2 | 1918470 | The pharmacology of methotrexate. | J Am Acad Dermatol | 1991 | https://conductscience.org/library/papers/1918470 | PubMed |
| 3 | 19741722 | Proteasome inhibitors in the treatment of multiple myeloma. | Leukemia | 2009 | https://conductscience.org/library/papers/19741722 | PubMed |
| 4 | 21224428 | Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | Mol Cancer Res | 2011 | https://conductscience.org/library/papers/21224428 | PubMed |
| 5 | 25629353 | DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. | PLoS Genet | 2015 | https://conductscience.org/library/papers/25629353 | PubMed |
| 6 | 8601652 | Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. | J Am Acad Dermatol | 1996 | https://conductscience.org/library/papers/8601652 | PubMed |
| 7 | 19274461 | Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. | Cancer Chemother Pharmacol | 2009 | https://conductscience.org/library/papers/19274461 | PubMed |
| 8 | 19201084 | The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. | Cancer Lett | 2009 | https://conductscience.org/library/papers/19201084 | PubMed |
| 9 | 21576575 | The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. | Arch Dermatol | 2011 | https://conductscience.org/library/papers/21576575 | PubMed |
| 10 | 14576667 | Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. | J Am Acad Dermatol | 2003 | https://conductscience.org/library/papers/14576667 | PubMed |
| 11 | 15692063 | WHO-EORTC classification for cutaneous lymphomas. | Blood | 2005 | https://conductscience.org/library/papers/15692063 | PubMed |
| 12 | 23181572 | From bortezomib to other inhibitors of the proteasome and beyond. | Curr Pharm Des | 2013 | https://conductscience.org/library/papers/23181572 | PubMed |
| 13 | 19016373 | Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. | J Dermatolog Treat | 2009 | https://conductscience.org/library/papers/19016373 | PubMed |
| 14 | 23045584 | Emerging treatment options for advanced-stage mycosis fungoides. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/23045584 | PubMed |
| 15 | 25336628 | Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. | Blood | 2015 | https://conductscience.org/library/papers/25336628 | PubMed |
| 16 | 11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | Cancer Res | 2001 | https://conductscience.org/library/papers/11306489 | PubMed |
| 17 | 18158775 | Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. | Cancer Biother Radiopharm | 2007 | https://conductscience.org/library/papers/18158775 | PubMed |
| 18 | 25305590 | A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. | J Proteomics | 2015 | https://conductscience.org/library/papers/25305590 | PubMed |
| 19 | 22377766 | MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. | J Invest Dermatol | 2012 | https://conductscience.org/library/papers/22377766 | PubMed |
| 20 | 25592781 | Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. | Hematology | 2015 | https://conductscience.org/library/papers/25592781 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42823576 | Polymeric micelle delivery of a HER2-selective tyrosine kinase inhibitor for targeted breast cancer therapy. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42823576 | PubMed |
| 33313939 | Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome. | Acta Derm Venereol | 2021 | https://conductscience.org/library/papers/33313939 | PubMed |
| 30993483 | Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. | Int J Clin Oncol | 2019 | https://conductscience.org/library/papers/30993483 | PubMed |
| 29572582 | Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. | Curr Oncol Rep | 2018 | https://conductscience.org/library/papers/29572582 | PubMed |
Genes50
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28107479
GET https://conductscience.org/api/papers/v1/28107479/references?page=2